51 search results for: Atopic Dermatitis
ADVENT at EADV 2024
Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
ADVENT On Air | Expert Discussions in Dermatology
Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.
Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the prevalence of food sensitization and food allergy in pediatric patients with AD, clarifying the difference between the two. Dr Boguniewicz also discusses the prevalence of other atopic comorbidities in children with AD
Matthew Zirwas, MD
Matthew Zirwas, MD, is an American Board of Dermatology-certified physician. He is a nationally known expert who has been specializing in contact dermatitis, pruritus, atopic dermatitis, and seborrheic dermatitis for the last 20 years.
ADVENT at EAACI PAAM 2025
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis, and eosinophilic esophagitis.
Bob Geng, MD
Co-Director of the Multidisciplinary Atopic Dermatitis Program | Rady Children's Hospital, San Diego | Associate Clinical Professor | UC San Diego School of Medicine, California, United States
Charting the Future: Preventing the Atopic March
In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga highlights the multidimensional burden of uncontrolled AD and how the various burdens contribute to Cumulative Life Course Impairment (CLCI).
Diving Below the Surface of AD: The Role of Type 2 Inflammation
This video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, features Dr. Stephan Weidinger discussing how local type 2 inflammation at the skin tissue level contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weidinger also reviews how systemic inflammation affects organ systems beyond the skin and can manifest as atopic and non-atopic comorbidities.
The Role of Type 2 Inflammation in Moderate-to-Severe AD
In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to the systemic inflammation seen in patients with moderate-to-severe AD.
Considerations for Disease Modification in AD
In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of disease modification and how early intervention might be disease modifying in AD.
